Kura Oncology, Inc. financial data

Symbol
KURA on Nasdaq
Industry
Pharmaceutical Preparations
Location
12730 High Bluff Drive, Suite 400, San Diego, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
ZETA ACQUISITION CORP III (to 3/10/2015)
Latest financial report
Q1 2024 - May 2, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.61K % -21.3%
Debt-to-equity 10 % +44%
Return On Equity -37.5 % -15%
Return On Assets -34.1 % -11.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 76.2M shares +11.3%
Common Stock, Shares, Outstanding 76.2M shares +11.3%
Entity Public Float 777M USD -35.3%
Common Stock, Value, Issued 8K USD +14.3%
Weighted Average Number of Shares Outstanding, Basic 83.9M shares +22.7%
Weighted Average Number of Shares Outstanding, Diluted 83.9M shares +22.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 126M USD +30.1%
General and Administrative Expense 57.4M USD +23.2%
Nonoperating Income (Expense) 15.6M USD +152%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -168M USD -22.3%
Earnings Per Share, Basic -2.17 USD/shares -6.37%
Earnings Per Share, Diluted -2.17 USD/shares -6.37%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 41.5M USD +53.4%
Assets, Current 538M USD +29.1%
Property, Plant and Equipment, Net 1.71M USD -27.9%
Operating Lease, Right-of-Use Asset 6.7M USD +97.5%
Other Assets, Noncurrent 7.67M USD +116%
Assets 554M USD +30%
Accounts Payable, Current 7.53M USD +129%
Employee-related Liabilities, Current 6.06M USD +19.4%
Liabilities, Current 32.3M USD +67.8%
Operating Lease, Liability, Noncurrent 6.23M USD +210%
Other Liabilities, Noncurrent 951K USD +171%
Liabilities 48.8M USD +58.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -816K USD +86.2%
Retained Earnings (Accumulated Deficit) -771M USD -27.9%
Stockholders' Equity Attributable to Parent 505M USD +27.8%
Liabilities and Equity 554M USD +30%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -48.8M USD -36.2%
Net Cash Provided by (Used in) Financing Activities 94.8M USD +146%
Net Cash Provided by (Used in) Investing Activities -95.3M USD -957%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 76.2M shares +11.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 4.19M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 41.5M USD +53.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.06M USD +1358%
Deferred Tax Assets, Valuation Allowance 224M USD +27.1%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 226M USD +27.4%
Operating Lease, Liability 7.59M USD +75%
Depreciation 234K USD +13.6%
Payments to Acquire Property, Plant, and Equipment 84K USD +133%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -163M USD -19.2%
Lessee, Operating Lease, Liability, to be Paid 10.9M USD +138%
Property, Plant and Equipment, Gross 4.37M USD +4.55%
Operating Lease, Liability, Current 1.36M USD -41.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.34M USD +44.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.96M USD +5.42%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure +90.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.3M USD +1271%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.37M USD
Deferred Tax Assets, Operating Loss Carryforwards 144M USD +14.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 10.1M USD +56%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.4M USD
Operating Lease, Payments 500K USD -16.7%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.34M USD -28.6%
Interest Expense 1.58M USD +9.34%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%